Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Down 22.0% in October

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 52,600 shares, a drop of 22.0% from the October 15th total of 67,400 shares. Based on an average daily volume of 47,600 shares, the short-interest ratio is currently 1.1 days.

Evaxion Biotech A/S Stock Down 14.3 %

NASDAQ EVAX traded down $0.24 on Friday, hitting $1.44. 76,290 shares of the company’s stock were exchanged, compared to its average volume of 28,397. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. The firm’s 50-day moving average price is $2.77 and its two-hundred day moving average price is $3.06. Evaxion Biotech A/S has a fifty-two week low of $1.40 and a fifty-two week high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.08. The company had revenue of $3.02 million for the quarter, compared to analyst estimates of $0.19 million. On average, sell-side analysts anticipate that Evaxion Biotech A/S will post -0.15 earnings per share for the current year.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Armistice Capital LLC raised its stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 392,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Armistice Capital LLC owned about 7.24% of Evaxion Biotech A/S worth $1,137,000 at the end of the most recent reporting period. 11.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.